Evidence map›Paper›PMID 39662854›Full record

ArticleInternational journal of pharmaceutics2025

Tumor specific delivery and radiation-enhanced tumor penetration of mesoporous silica nanoparticles for effective radionuclide therapy of ovarian peritoneal metastasis.

Derek Hargrove, Sheyda Ranjbar, Mittal Darji, Sangho Nam, Robert J Dawson, Sumudu Katugampola, Xinhao Lin, Amy Brown, Natalia Carrasco-Rojas, Cameron Goodwin and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Small (Weinheim an der Bergstrasse, Germany) · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Derek HargroveDepartment of Pharmaceutical Sciences, University of Connecticut, Storrs, CT, USA.
Sheyda RanjbarDepartment of Pharmaceutical Sciences, University of Connecticut, Storrs, CT, USA.
Mittal DarjiDepartment of Pharmaceutical Sciences, University of Connecticut, Storrs, CT, USA.
Sangho NamRhode Island Nuclear Science Center, RI, USA.
Robert J DawsonJ. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Orlando, FL, USA.
Sumudu KatugampolaDepartment of Radiology, Rutgers New Jersey Medical School, NJ, USA.
Xinhao LinDepartment of Pharmaceutical Sciences, University of Connecticut, Storrs, CT, USA.
Amy BrownHartford Healthcare Medical Group, Hartford, CT, USA.
Natalia Carrasco-RojasJ. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Orlando, FL, USA.
Cameron GoodwinRhode Island Nuclear Science Center, RI, USA.
Roger W HowellDepartment of Radiology, Rutgers New Jersey Medical School, NJ, USA.
Wesley E BolchJ. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Orlando, FL, USA.
Michael JayEshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA; Nami Therapeutics Corporation. Storrs, CT, USA.
Andrew SalnerHartford Healthcare Medical Group, Hartford, CT, USA.
Xiuling LuDepartment of Pharmaceutical Sciences, University of Connecticut, Storrs, CT, USA. Electronic address: xiuling.lu@uconn.edu.

Funding

Nanoparticle-based Intraperitoneal Delivery of Combined Chemo-radiotherapy for Treatment of Ovarian Cancer MetastasesR44CA239989 · NCI · NAMI THERAPEUTICS CORP. · PI JAY, MICHAEL · 2022 to 2023
$2.0M
MIRDcell Version 3R01CA245139 · NCI · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI Roger W. Howell · 2020 to 2026
$1.8M
Nanoparticle-based Intraperitoneal Delivery of Combined Chemo-brachytherapy for Treatment of Ovarian Cancer MetastasesR41CA239989 · NCI · NAMI THERAPEUTICS CORP. · PI LU, XIULING · 2019 to 2019
$225k
NCI NIH HHS R01 CA245139NCI NIH HHS R41 CA239989NCI NIH HHS R44 CA239989
6 · The paper itself

Abstract

Advanced ovarian cancer with peritoneal metastasis is challenging to treat. Limited tumor delivery and penetration of the therapeutics to deep tumor regions are significant barriers to effective treatment. The rising radiopharmaceuticals offer hopes for patients through targeted delivery. However, site specific delivery avoiding off target effect remain critical and challenging. We have developed radioactive

Indexed as

NanoparticlesOvarian NeoplasmsPeritoneal NeoplasmsSilicon DioxideAnimalsCell Line, TumorDrug Delivery SystemsFemaleHumansMiceMice, Inbred BALB CMice, NudePorosityRadioisotopesRadiopharmaceuticalsTissue DistributionRadioisotopesRadiopharmaceuticalsSilicon DioxideHolmiun-166Internal radiation therapyIntraperitoneal deliveryNeutron activationOvarian cancerPeritoneal metastasis

Identifiers

PMID39662854
PMCPMC11791539

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.